510(k) Report

510(k) · Cleared

Cleared

MammoScreen 2.0

K211541510(k) TraditionalCleared Nov 26, 2021191-day reviewClass II21 CFR 892.2090

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Therapixel · QDQ Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer

Cleared on Nov 26, 2021 as substantially equivalent to K192854 (Therapixel, 2020) after a 191-day review. Its family tree reaches back 3 generations to 2018. 3 later devices descend from it.

Decided
Nov 26, 2021
Review
191 days
Class
Class II
Product code
QDQ
Recalls
None
Predicates
1

Its longest line of descent runs back 3 generations to DEN180005 (2018). 3 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2024: 1 descendant cleared2025: 1 descendant cleared2026: 1 descendant clearedDEN180005 · OsteoDetect · Imagen Technologies, Inc. · 2018K181704 · Transpara · Screenpoint Medical B.V. · 2018K192854 · MammoScreen · Therapixel · 2020201620182020202220242026
Descendants, by generation 1 generation forward: 1 descendant2 generations forward: 1 descendant3 generations forward: 1 descendant K192854 · MammoScreen · Therapixel · 2020K181704 · Transpara · Screenpoint Medical B.V. · 2018DEN180005 · OsteoDetect · Imagen Technologies, Inc. · 20180
  1. Root · 3 generations backDEN180005 OsteoDetectImagen Technologies, Inc. · 2018
  2. 2 generations backK181704 TransparaScreenpoint Medical B.V. · 2018
  3. 1 generation backK192854 MammoScreenTherapixel · 2020
  4. This deviceK211541 MammoScreen 2.0Therapixel · 2021
  5. Descendant · cites it directly · 2 of its ownK240301 MammoScreen® (3)Therapixel · 2024
  6. Descendant · 2 generations on · 1 of its ownK243679 MammoScreen® (4)Therapixel · 2025
  7. Descendant · 3 generations on · 0 of its ownK260714 MammoScreen® (5)Therapixel · 2026

Most influential descendants

Showing 3 of 3 · See all
  • K240301MammoScreen® (3)Therapixel · 2024 · cites it directly2descendants
  • K243679MammoScreen® (4)Therapixel · 2025 · 2 generations on1descendant
  • K260714MammoScreen® (5)Therapixel · 2026 · 3 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−3DEN180005OsteoDetectImagen Technologies, Inc.2018—
−2K181704TransparaScreenpoint Medical B.V.2018—
−1K192854MammoScreenTherapixel2020—
0 (this device)K211541MammoScreen 2.0Therapixel2021—
+1K240301MammoScreen® (3)Therapixel2024—
+2K243679MammoScreen® (4)Therapixel2025—
+3K260714MammoScreen® (5)Therapixel2026—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202410
202510
202610
FIG. 1 — Lineage of K211541, 2018–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QDQ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QDQ device

  1. #1 K241831 Transpara (2.1.0)score 15.6 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K192854MammoScreen
Summary page 5
…QDQ Submission type Traditional 510(k) 510(k) number: K211541 Predicate Device: The predicate device is MammoScreen, cleared under K192854. Device Description: MammoScreen 2.0 automatically processes the four views (one CC and one MLO per breast) of standard screenin…
Therapixel2020—

What descends from it? (3)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K240301MammoScreen® (3)Therapixel20242

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 3 years and passes through 3 companies; a new generation was cleared every 1.3 years on median.
  • None of the 3 ancestors has a recall.
  • Of its descendants, K240301 (Therapixel, 2024) has gone furthest, with 2 descendants of its own.

How does its category compare?

All QDQ devices

QDQ Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · QDQ

10so far in 2026, the most since 2007

2018: 22019: 22020: 32021: 52022: 42023: 22024: 72025: 52026 (partial year): 10
2007high 10 (2026) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QDQ

216in 2025

2020: 173 days median2021: 169 days median2022: 131 days median2024: 153 days median2025: 216 days median2026 (partial year): 154 days median
2007high 216 (2025) · low 131 (2022)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QDQ

No recall names QDQ since 2007.

Adverse event reports per year · QDQ

No MAUDE report names QDQ since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20182—00
20192—00
2020317300
2021516900
2022413100
20232—00
2024715300
2025521600
2026101540—

What is it indicated for?

MammoScreen® is intended for use as a concurrent reading aid for interpreting physicians, to

help identify findings on screening FFDM and DBT acquired with compatible mammography

systems and assess their level of suspicion. Output of the device includes marks placed on findings

on the mammogram and level of suspicion scores. The findings could be soft tissue lesions or

calcifications. The level of suspicion score is expressed at the finding level, for each breast and

overall for the mammogram. Patient management decisions should not be made solely on the basis

of analysis by MammoScreen®.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K211541: MammoScreen 2.0.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K211541

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026